Brain-Penetrant Covalent BChE Inhibitor Shows Procognitive Effects in Alzheimer's Model
- Researchers used structure-guided design to develop a covalent small-molecule inhibitor of human butyrylcholinesterase (BChE), an enzyme increasingly implicated in Alzheimer's disease progression.
- The lead compound was engineered for blood-brain barrier penetration, a key hurdle for centrally acting cholinesterase inhibitors.
- In vivo testing showed procognitive efficacy, supporting covalent BChE inhibition as a potential treatment approach for Alzheimer's disease.
💡 Points
BChE rising while AChE falls late in disease is finally moving the field past AChE-centric dogma. A covalent warhead in a serine hydrolase family full of close paralogs (AChE, esterases) needs hard selectivity data, not just potency. What actually differentiates this from rivastigmine-class reversible inhibitors is CNS penetration — brain exposure they never solved well.